nach oben

Erschienen in:

01.04.2020 | Sleep Disorders (A Iranzo, Section Editor)

Iron Replacement Therapy in Restless Legs Syndrome

verfasst von: Celia Garcia-Malo, MD, Carolina Miranda, MD, Sofia Romero Peralta, MD, Irene Cano-Pumarega, MD, PhD, Sabela Novo Ponte, MD, Diego Garcia-Borreguero, MD, PhD

Erschienen in: Current Treatment Options in Neurology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

The main purpose of this manuscript is to review the existing clinical evidence about when iron replacement therapy should be initiated for RLS/WED, and how it should be administered (oral vs. intravenous).

Recent findings

Our knowledge of the pathophysiology of restless legs syndrome/Willis-Ekbom (RLS/WED) continues to grow, revealing the existence of brain iron deficiency as the most well-known biological alteration behind this disorder. Since iron replacement therapy in RLS/WED is one of the first-line available treatments, its indication should be considered periodically, at both the beginning and during the follow-up.

Summary

There is more and more evidence sustaining that the proper use of iron replacement therapy may lead to a reduction in symptomatic drug requirements, and therefore minimize the risk of complications that may result from their long-term use. For all the above, treatment paradigms for RLS/WED, previously based on symptomatic drugs, are changing, giving iron replacement therapy the importance it merits. Thus, it is essential for neurologists to be updated on why, when, and how to use iron in RLS/WED.

Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16:283–95.PubMed

Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria - history, rationale, description, and significance. Sleep Med. 2014;15:860–73.PubMed

Earley CJ, Silber MH. Restless legs syndrome: understanding its consequences and the need for better treatment. Sleep Med. 2010;11:807–15.PubMed

Ferri R, Koo BB, Picchietti DLFS. Periodic leg movements during sleep: phenotype, neurophysiology, and clinical significance. Sleep Med. 2017;31:29–38.PubMed

Winkelman JW, Shahar E, Sharief IGD. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology. 2008;70:35–42.PubMed

Trenkwalder C, Allen R, Högl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases. Neurology. 2016;86:1336–43.PubMedPubMedCentral

Pantaleo NP, Hening WA, Allen RP, et al. Pregnancy accounts for most of the gender difference in prevalence of familial RLS. Sleep Med. 2010;11:310–3.PubMed

Wanner V, Garcia Malo C, Romero S, Cano-Pumarega I, García-Borreguero D. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome. Adv Pharmacol. 2019;84:187–205.PubMed

Garcia-Borreguero D, Silber MH, Winkelman JW, Högl B, Bainbridge J, Buchfuhrer M, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11.PubMed

10.•

Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med. 2018;41:27–44 These are the current guidelines made by the International RLS Study Group regarding iron replacement therapy, including several useful algorithms.

11.

Allen RP, Adler CH, Du W, et al. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011;12:906–13.PubMed

12.

Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep. 1998;21:371–7.PubMed

13.

Rizzo G, Li X, Galantucci S, Filippi M, Cho YW. Brain imaging and networks in restless legs syndrome. Sleep Med. 2017;31:39–48.PubMed

14.

Earley CJ, Barker BP, Horská A, et al. MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. Sleep Med. 2006;7:458–61.PubMed

15.

Provini F, Chiaro G. Neuroimaging in restless legs syndrome. Sleep Med Clin. 2015;10:215–26.PubMed

16.

Godau J, Sojer M. Transcranial sonography in restless legs syndrome. Int Rev Neurobiol. 2010;90:199–215.PubMed

17.

Connor J, Boyer P, Menzies S, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003;61:304–9.PubMed

18.

Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54:1698–700.PubMed

19.

Mizuno S, Mihara T, Miyaoka T, Inagaki T, Horiguchi J. CSF iron, ferritin and transferrin levels in restless legs syndrome. J Sleep Res. 2005;14:43–7.PubMed

20.

Winkelmann J, Schormair B, Xiong L, Dion PA, Rye DB, Rouleau GA. Genetics of restless legs syndrome. Sleep Med. 2017;31:18–22.PubMed

21.

Ferré S, Quiroz C, Guitart X, et al. Pivotal role of adenosine neurotransmission in restless legs syndrome. Front Neurosci. 2018;11:1–14.

22.

Yepes G, Guitart X, Rea W, Newman AH, Allen RP, Earley CJ, et al. Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Ann Neurol. 2017;82:951–60.PubMedPubMedCentral

23.

Rizzo G, Manners D, Testa C, et al. Low brain iron content in idiopathic restless legs syndrome patients detected by phase imaging. Mov Disord. 2013;28:1886–90.PubMed

24.

Allen RP, Barker PB, Wehrl FW, Song HKEC. MRI measurement of brain iron in patients with restless legs syndrome. Neurology. 2001;56:263–5.PubMed

25.

Lanza G, Ferri R. The neurophysiology of hyperarousal in RLS: hints for a role of glutamate/GABA. Advances in Pharmacology. 2019;84:101–119. https://doi.org/10.1016/bs.apha.2018.12.002

26.

Ferré S, García-Borreguero D, Allen RPEC. New insights into the neurobiology of restless legs syndrome. Neuroscientist. 2019;25:113–25.PubMed

27.

Becker G, Berg D. Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound. Mov Disord. 2001;16:23–32.PubMed

28.

Vivó-Orti MN, Tembl JI, Sastre-Bataller I, et al. Evaluación de la sustancia negra mediante ultrasonografía transcraneal. Rev Neurol. 2013;56:268–74.PubMed

29.

Sanzaro E, Iemolo F. Transcranial sonography in movement disorders: an interesting tool for diagnostic perspectives. Neurol Sci. 2016;37:373–6.PubMed

30.

Berg D. In vivo detection of iron and neuromelanin by transcranial sonography - a new approach for early detection of substantia nigra damage. J Neural Transm. 2006;113:775–80.PubMed

31.

Schmidauer C, Sojer M, Seppi K, et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol. 2005;54:630–4.

32.

Godau J, Schweitzer KJ, Liepelt I, Gerloff CBD. Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome. Mov Disord. 2007;22:187–92.PubMed

33.

Godau J, Wevers AK, Gaenslen A, di Santo A, Liepelt I, Gasser T, et al. Sonographic abnormalities of brainstem structures in restless legs syndrome. Sleep Med. 2008;9:782–9.PubMed

34.•

Garcia-Malo C, Wanner V, Miranda C, Romero Peralta S, Agudelo L, Cano-Pumarega I, et al. Quantitative transcranial sonography of the substantia nigra as a predictor of therapeutic response to intravenous iron therapy in restless legs syndrome. Sleep Med. 2019;66:123–9 This study found that transcranial sonography is a useful tool that helps in selecting which patients could benefit most from IV iron.PubMed

35.

Ganz T. Anemia of inflammation. N Engl J Med. 2019;381:1148–57.PubMed

36.

Waldvogel-Abramowski S, Waeber G, Gassner C, Buser A, Frey BM, Favrat BTJ. Physiology of iron metabolism. Transfus Med Hemother. 2014;41:213–21.PubMedPubMedCentral

37.

Singh N, Haldar S, Tripathi AK, Horback K, Wong J, Sharma D, et al. Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal. 2014;20:1324–63.PubMedPubMedCentral

38.

Muckenthaler MU. Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab. 2008;8:1–3.PubMed

39.

Watson J, Round AHW. Raised inflammatory markers. BMJ. 2012;344:e454.PubMed

40.

LA Pfeiffer CM. Laboratory methodologies for indicators of iron status: strengths, limitations, and analytical challenges. Am J Clin Nutr. 2017;106:1606S–14S.PubMedPubMedCentral

41.

Ridefelt P, Larsson A, Rehman JUAJ. Influences of sleep and the circadian rhythm on iron-status indices. Clin Biochem. 2010;43:323–8.

42.

Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, et al. Altered brain iron homeostasis and dopaminergic function in restless legs syndrome (Willis-Ekbom disease). Sleep Med. 2014;15:1288–301.PubMed

43.

Powell LW. Diagnosis of hemochromatosis. Semin Gastrointest Dis. 2002;13:80–8.PubMed

44.

Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA. 2001;285:2216–22.PubMed

45.

Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:675–84.PubMed

46.

Cho YW, Allen RP, Earley CJ. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Med. 2016;25:16–23.PubMed

47.

Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10:e0117383.PubMedPubMedCentral

48.

Davis BJ, Rajput A, Rajput ML, et al. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol. 2000;43:70–5.PubMed

49.

Wang J, O’Reilly B, Venkataraman R, et al. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study. Sleep Med. 2009;10:973–5.PubMed

50.

Lee CS, Lee SD, Kang SH, Park HY, Yoon IY. Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndrome patients with low serum ferritin. Eur J Neurol. 2014;21:260–6.PubMed

51.

Stoffel N, Cercamondi C, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017;4:e524–33.PubMed

52.

Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126:1981–9.PubMed

53.

Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levenson M, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314:2062–8.

54.

Tomer A, Amir B, Alon G, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90:12–23.

55.

DeLoughery TG. Safety of oral and intravenous iron. Acta Haematol. 2019;142:8–12.PubMed

56.•

Trenkwalder C, Winkelmann J, Oertel W, Virgin G, Roubert B, Mezzacasa A, et al. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: a randomized trial. Mov Disord. 2017;32:1478–82 This is to date the study with the highest number of RLS patients comparing IV iron (FCM) vs. placebo.PubMedPubMedCentral

57.

Cho YW, Allen RP, Earley CJ. Efficacy of ferric carboxymaltose (FCM) 500 mg dose for the treatment of restless legs syndrome. Sleep Med. 2018;42:7–12.PubMed

58.

Mehmood T, Auerbach M, Earley CJ, Allen RP. Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome (Willis-Ekbom disease). Sleep Med. 2014;15:1473–6.PubMed

59.

Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord. 2009;24:1445–52.PubMed

Titel: Iron Replacement Therapy in Restless Legs Syndrome
verfasst von: Celia Garcia-Malo, MD
Carolina Miranda, MD
Sofia Romero Peralta, MD
Irene Cano-Pumarega, MD, PhD
Sabela Novo Ponte, MD
Diego Garcia-Borreguero, MD, PhD
Publikationsdatum: 01.04.2020
Verlag: Springer US
Erschienen in: Current Treatment Options in Neurology / Ausgabe 4/2020
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-020-0617-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen